NCT04825106 (ANASim) is a NA clinical trial of Diagnostic context in Diagnostic Error, sponsored by University Hospital, Basel, Switzerland.

Who is sponsoring NCT04825106?

NCT04825106 is sponsored by University Hospital, Basel, Switzerland.

What drugs are being tested in NCT04825106?

Interventions in NCT04825106: Diagnostic context.

What condition does NCT04825106 study?

NCT04825106 studies Diagnostic Error.

Is NCT04825106 still recruiting?

NCT04825106 is currently completed. Last updated 11 May 2023.

Last reviewed 2023-05-11 · How we verify

NCT04825106: ANASim

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diagnostic Errors in Anaphylactic Shock

Completed NA Last updated 11 May 2023

What this trial tests

NA trial testing Diagnostic context in Diagnostic Error in 270 participants. Completed in 31 December 2022.

Timeline

1 January 2008

Primary endpoint
30 November 2022

31 December 2022

Quick facts

Lead sponsor	University Hospital, Basel, Switzerland
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	diagnostic
Enrollment	270
Start date	1 January 2008
Primary completion	30 November 2022
Estimated completion	31 December 2022
Sites	1 location across Switzerland

Drugs / interventions tested

Diagnostic context

Conditions studied

Diagnostic Error — all drugs for Diagnostic Error →

Sponsor

University Hospital, Basel, Switzerland

Who can join

24 and older, any sex, with Diagnostic Error. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Diagnostic accuracy and quality of management in anaphylactic shock is assessed in three conditions: expected, unexpected with no distractor, unexpected with distractor

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04825106 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
Last refreshed: 11 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04825106.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing